Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
Analyses of pooled efficacy data from the EMERGENT program demonstrate significant improvements in schizophrenia symptoms Analyses extend prior findings that KarXT... Read more.
Materion Corporation Reports Record Third Quarter 2023 Results
MAYFIELD HEIGHTS, Ohio–(BUSINESS WIRE)–Materion Corporation (NYSE: MTRN) today reported third quarter financial results and affirmed the midpoint of... Read more.
Ferguson plc: Block Listing Six Monthly Return
WOKINGHAM, England–(BUSINESS WIRE)– Name of applicant: Ferguson plc Name of scheme: Ferguson Group International Sharesave Plan 2011 Period of return:... Read more.
ATS to Participate in the Baird 2023 Global Industrial Conference
CAMBRIDGE, Ontario–(BUSINESS WIRE)–ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), an industry-leading automation solutions provider,... Read more.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Approval based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated significant overall survival benefit in these patients versus chemotherapy alone... Read more.
The Estée Lauder Companies Reports Fiscal 2024 First Quarter Results
Net Sales Decreased 10% and Diluted EPS Declined to $.09 Organic Net Sales1 Declined 11% and Adjusted Diluted EPS Decreased to $.11 Delivered First Quarter Expectations... Read more.
Kolibri Global Energy Inc. Announces Bank Line Redetermination
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Kolibri Global Energy Inc. (the “Company” or “KEI”) (TSX: KEI, NASDAQ: KGEI) is pleased to announce the... Read more.
IDEXX Laboratories Announces Third Quarter Results
Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic Solid revenue... Read more.
Humana Reports Third Quarter 2023 Financial Results; Affirms Full Year 2023 Adjusted EPS Guidance
Reports 3Q23 earnings per share (EPS) of $6.71 on a GAAP basis, Adjusted EPS of $7.78; reports YTD 2023 EPS of $24.26 on a GAAP basis, $26.10 on an Adjusted basis... Read more.
Karuna Therapeutics to Present at Upcoming Investor Conferences
BOSTON–(BUSINESS WIRE)–Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative... Read more.